PARI Pharma
PARI GmbH specializes in developing and manufacturing advanced aerosol delivery systems based on eFlow Technology, with a focus on inhalation therapies. They offer a broad platform of nebulizer systems that are designed to improve drug deposition in the respiratory tract, reduce treatment burden, and support pharmaceutical partners in drug development, customization, and commercialization. With over 20 years of expertise, PARI is committed to providing reliable, high-quality nebulizers and digital health solutions to enhance patient adherence and clinical outcomes.
Industries
Nr. of Employees
small (1-50)
PARI Pharma
Lochhamer Schlag 21, 82166 Gräfelfing / Munich, Germany
Patents
Aerosol delivery device and operating method for the aerosol delivery device
US-11547822-B2
View Details
Aerosol delivery device and operating method for the aerosol delivery device
US-11547822-B2
View DetailsProducts
Vibrating-mesh nebulizer platform (open-system)
A highly efficient vibrating-mesh nebulizer platform configurable for multiple formulations, designed for short nebulization times and high lung delivery efficiency.
Breath-triggered / integrated nebulizer platform
An integrated, breath‑triggered nebulizer platform that guides inhalation and is designed to improve delivery efficiency through breath‑synchronized aerosol generation.
Closed-system nebulizer with prefilled ampoule
A nebulizer design that uses a prefilled, sealed ampoule-style reservoir inserted into the device to reduce manual handling, contamination risk and dosing errors.
Digital therapy management platform (device + app + dashboard)
A digital ecosystem that links nebulizer devices to a patient mobile app and clinician/study dashboards to capture objective usage data, enable coaching, and monitor adherence remotely.
Vibrating-mesh nebulizer platform (open-system)
A highly efficient vibrating-mesh nebulizer platform configurable for multiple formulations, designed for short nebulization times and high lung delivery efficiency.
Breath-triggered / integrated nebulizer platform
An integrated, breath‑triggered nebulizer platform that guides inhalation and is designed to improve delivery efficiency through breath‑synchronized aerosol generation.
Closed-system nebulizer with prefilled ampoule
A nebulizer design that uses a prefilled, sealed ampoule-style reservoir inserted into the device to reduce manual handling, contamination risk and dosing errors.
Digital therapy management platform (device + app + dashboard)
A digital ecosystem that links nebulizer devices to a patient mobile app and clinician/study dashboards to capture objective usage data, enable coaching, and monitor adherence remotely.
Services
In-vitro aerosol performance testing (NGI, laser diffraction, breath simulation) and report generation performed under GMP and ISO 13485 controls to support feasibility assessments and regulatory submissions.
Tailoring of nebulizer components (mesh, aerosol head, reservoir, valved chambers) and device configurations to improve delivery efficiency and reduce nebulization time for specific drug formulations.
Provision of investigational nebulizers, supply planning for clinical programs, and digital monitoring tools to reduce variability and improve adherence during trials.
User requirements definition, iterative usability testing and validation studies with target patient groups to support safe and effective use and regulatory submissions.
Deployment of an integrated system to record inhalation events, monitor adherence remotely, deliver patient coaching, and provide dashboards for clinicians and study personnel.
Automated production, in-process control, multi-site manufacturing capacity and supply chain management to transition devices from clinical batches to commercial volumes.
In-vitro aerosol performance testing (NGI, laser diffraction, breath simulation) and report generation performed under GMP and ISO 13485 controls to support feasibility assessments and regulatory submissions.
Tailoring of nebulizer components (mesh, aerosol head, reservoir, valved chambers) and device configurations to improve delivery efficiency and reduce nebulization time for specific drug formulations.
Provision of investigational nebulizers, supply planning for clinical programs, and digital monitoring tools to reduce variability and improve adherence during trials.
User requirements definition, iterative usability testing and validation studies with target patient groups to support safe and effective use and regulatory submissions.
Deployment of an integrated system to record inhalation events, monitor adherence remotely, deliver patient coaching, and provide dashboards for clinicians and study personnel.
Automated production, in-process control, multi-site manufacturing capacity and supply chain management to transition devices from clinical batches to commercial volumes.
Expertise Areas
- Nebulizer development and formulation-specific device optimization
- Aerosol characterization and analytical testing for inhalation products
- Human factors, usability studies and adherence optimization
- Clinical trial device supply and trial-support services
Key Technologies
- Vibrating-mesh (vibrating-membrane) nebulization
- Laser-drilled micro-mesh fabrication
- Closed-system prefilled ampoule delivery for nebulizers
- Breath-triggered and breath-guiding nebulization
News & Updates
Savara Inc. submitted a BLA to the FDA for MOLBREEVI, an inhaled biologic administered via an optimized eFlow® nebulizer.
Insmed reports positive data from the ARISE trial of ARIKAYCE, delivered via an optimized eFlow® nebulizer.
Polyphor received approval to initiate a first-in-human trial of inhaled murepavadin, administered via an eFlow® nebulizer.
The Magnair™ nebulizer, designed and developed by PARI, received FDA approval for use with Sunovion’s Lonhala™ in COPD treatment.
PARI’s LAMIRA® nebulizer system, optimized for ARIKAYCE®, received CE marking and approval for treating MAC lung infections in Europe.
LONHALA MAGNAIR, an eFlow®-based product, was the first to receive FDA approval for COPD treatment in the US.
Savara Inc. submitted a BLA to the FDA for MOLBREEVI, an inhaled biologic administered via an optimized eFlow® nebulizer.
Insmed reports positive data from the ARISE trial of ARIKAYCE, delivered via an optimized eFlow® nebulizer.
Polyphor received approval to initiate a first-in-human trial of inhaled murepavadin, administered via an eFlow® nebulizer.
The Magnair™ nebulizer, designed and developed by PARI, received FDA approval for use with Sunovion’s Lonhala™ in COPD treatment.
PARI’s LAMIRA® nebulizer system, optimized for ARIKAYCE®, received CE marking and approval for treating MAC lung infections in Europe.
LONHALA MAGNAIR, an eFlow®-based product, was the first to receive FDA approval for COPD treatment in the US.